Beremagene geperpavec (dystrophic epidermolysis bullosa) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V

Report documents

1. Dossier assessment

   Beremagen geperpavec (dystrophe Epidermolysis bullosa) – Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V

   published on

   17.11.2025

   Document type

   PDF-Dokument, 320 kB, DE, PDF

   DOI-Link

   https://doi.org/10.60584/G25-25

   Download file : Dossier assessment (PDF-Dokument, 320 kB, DE, PDF)

Project details

Project no.

G25-25

Commission

Commission awarded on 15.08.2025 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Health Economics

Topic

Skin and hair

Note

In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.

After completion of the assessment by IQWiG, the GBA conducts a commenting procedure. Following the hearing, the GBA decides on the extent of the added benefit. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA Website.

DOI

https://doi.org/10.60584/G25-25